Vis enkel innførsel

dc.contributor.authorColombo, Francesca
dc.contributor.authorPintarelli, Giulia
dc.contributor.authorGalvan, Antonella
dc.contributor.authorNoci, Sara
dc.contributor.authorCorli, Oscar
dc.contributor.authorSkorpen, Frank
dc.contributor.authorKlepstad, Pål
dc.contributor.authorKaasa, Stein
dc.contributor.authorPigni, Alessandra
dc.contributor.authorBrunelli, Cinzia
dc.contributor.authorRoberto, Anna
dc.contributor.authorPiazza, Rocco
dc.contributor.authorPirola, Alessandra
dc.contributor.authorGambacorti-Passerini, Carlo
dc.contributor.authorCaraceni, Augusto Tomasso Giovanni
dc.date.accessioned2021-04-19T07:46:15Z
dc.date.available2021-04-19T07:46:15Z
dc.date.created2020-09-29T12:29:14Z
dc.date.issued2020
dc.identifier.citationScientific Reports. 2020, 10 (1), .en_US
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/11250/2738242
dc.description.abstractNausea and vomiting are often associated with opioid analgesia in cancer patients; however, only a subset of patients develop such side effects. Here, we tested the hypothesis that the occurrence of nausea and vomiting is modulated by the genetic background of the patients. Whole exome sequencing of DNA pools from patients with either low (n = 937) or high (n = 557) nausea and vomiting intensity, recruited in the European Pharmacogenetic Opioid Study, revealed a preliminary association of 53 polymorphisms. PCR-based genotyping of 45 of these polymorphisms in the individual patients of the same series confirmed the association for six SNPs in AIM1L, CLCC1, MUC16, PDE3A, POM121L2, and ZNF165 genes. Genotyping of the same 45 polymorphisms in 264 patients of the Italian CERP study, also treated with opioids for cancer pain, instead confirmed the association for two SNPs in ZNF568 and PDE3A genes. Only one SNP, rs12305038 in PDE3A, was confirmed in both series, although with opposite effects of the minor allele on the investigated phenotype. Overall, our findings suggest that genetic factors are indeed associated with nausea and vomiting in opioid-treated cancer patients, but the role of individual polymorphisms may be weak.en_US
dc.language.isoengen_US
dc.publisherNature Portfolioen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleIdentification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patientsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber0en_US
dc.source.volume10en_US
dc.source.journalScientific Reportsen_US
dc.source.issue1en_US
dc.identifier.doi10.1038/s41598-019-57358-y
dc.identifier.cristin1834829
dc.description.localcodeThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.en_US
dc.source.articlenumber542en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal